Association of Analgesic Effects of Oxycodone Hydrochloride with the A118G of OPRM1 Genes in Patients with Cancer Pain / 医药导报

ABSTRACT

Objective To examine the relationship between the A118G polymorphism of mu-opioid receptor(OPRM1) gene and analgesic effects of oxycodone hydrochloride in patients with severe cancer pain. Methods Fifty-nine patients with severe cancer-induced pain were divided into 3 groups by genotype(AA group,AG group and GG group,23,28,8 patients, respectively). They were orally treated with oxycodone hydrochloride sustained-release tablets,and the treatment dosage and adverse reactions(including nausea,vomiting,dizziness,constipation,etc.)were compared between groups. Results The variation of allele frequencies(118G)was 37.3%.The dosage of oxycodone hydrochloride sustained-release tablets used in AA, AG and GG groups was(27.0±14.3),(36.4±22.5)and(55.0±35.1)mg,respectively,and the differences were statistically significant between groups( P = 0. 01). On the part of adverse reactions,the incidence of nausea and vomiting,dizziness, constipation was 28.8%,22.0%,and 52.5%,in AA,AG and GG groups,respectively,and there was no significant difference between groups(P>0.05). Conclusion The analgesic effect of oxycodone hydrochloride is affected by opioid receptor gene polymorphism.Patients with G allelic variation(AG or GG genotype)require larger doses of oxycodone hydrochloride than those with AA genotype.However,adverse reactions are not associated with polymorphism.